Treatment with monoclonal anti-tumor necrosis factor α antibody results in an accumulation of TH1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 42, Issue 10, 1999, Pages 2166-2173

  Maurice, Madelon M ^a   Van Der Graaff, Wiebo L ^b   Leow, Angela ^a   Breedveld, Ferdinand C ^a   Van Lier, René A W ^b   Verweij, Cornelis L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; HUMAN; LEUKOCYTE MIGRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033495918     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K     Document Type: Article

References (56)

1. Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, et al. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 1990;49:480-6.
2. Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
3. 486IL-2) in refractory rheumatoid arthritis: a double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum 1995;38:1177-86.
4. Kirkham BW, Thien F, Pelton BK, Pitzalis C, Amlot P, Denman AM, et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992;19:1348-52.
5. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
6. Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993;36:307-18.
7. Horneff G, Burmester GR, Emmerich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991;34:129-40.
8. Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmüller G, Krüger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151: clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991;34:525-36.
9. Didry C, Portalès P, Andary M, Brochier J, Combe B, Clot J, et al. Treatment of rheumatoid arthritis with monoclonal anti-CD4 antibodies: clinical results [abstract]. Arthritis Rheum 1991;34 Suppl 9:S92.
10. Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies. Arthritis Rheum 1993;36:620-30.
11. 389IL-2 administered to patients with active rheumatoid arthritis receiving treatment with methotrexate [abstract]. Arthritis Rheum 1994;37 Suppl 9:S341.
12. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
13. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992-9.
14. Wendling D, Radacot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20:259-62.
15. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;36:1681-90.
16. Moreland LW, Margolies GR, Heck LW, Saway PA, Jacobs C, Beck C, et al. Soluble tumor necrosis factor receptor: results of a phase I dose-escalation study in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1994;37 Suppl 9:S295.
17. Drevlow B, Lovis R, Haag MA, Sinacore J, Jacobs C, Blosch C, et al. Phase I study of recombinant human interleukin-1 receptor administered subcutaneously in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 1994;37 Suppl 9:S339.
18. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
19. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 1988;73:449-55.
20. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990;144:3347-53.
21. Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA. Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
22. Brennan FM, Maini RN, Feldmann M. Cytokine expression in chronic inflammatory disease. Br Med Bull 1995;51:368-84.
23. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;334:244-7.
24. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-8.
25. Feldmann M. What is the mechanism of action of anti-tumour necrosis factor-a antibody in rheumatoid arthritis? Int Arch Allergy Immunol 1996;111:362-5.
26. Bottomly K. A functional dichotomy in CD4+ T lymphocytes. Immunol Today 1988;9:268-74.
27. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
28. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991;12:256-7.
29. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635-73.
30. Charlton B, Lafferty KJ. The Th1/Th2 balance in autoimmunity. Curr Opin Immunol 1995;7:793-8.
31. Druet P, Sheela R, Pelletier L. Th1 and Th2 cells in autoimmunity. Clin Exp Immunol 1995;101 Suppl 1:9-12.
32. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
33. Knight DM, Trinh H, Le J. Construction and initial characterization of a mouse-human chimaeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
34. Jung T, Schauer U, Heusser C, Neuman C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993;159:197-207.
35. Hamann D, Baars PA, Hooibrink B, van Lier RAW. Heterogeneity of the human CD4+ T-cell population: two distinct CD4+ T-cell subsets characterized by coexpression of CD45RA and CD45RO isoforms. Blood 1996;9:3513-21.
36. + T lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation. J Immunol 1991;146:2088-94.
37. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
38. Lorenz H-M, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N, et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996;156:1646-53.
39. - subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol 1992;22:993-9.
40. + T cells. J Exp Med 1997;186:1407-18.
41. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
42. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR. Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
43. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci U S A 1994;91: 8562-6.
44. Dolhain RJEM, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AMM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1961-9.
45. Austrup F, Vestweber D, Borges E, Löhning M, Bräuer R, Herz U, et al. P-and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature 1997;385:81-3.
46. Van Roon JAG, Verhoef CM, van Roy JLAM, Gmelig-Meyling FHJ, Huber-Bruning O, Lafeber FPJG, et al. Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann Rheum Dis 1997;56:656-60.
47. Tak PP, Hintzen RQ, Teunissen JJ, Smeets TJ, Daha MR, van Lier RA, et al. Expression of the activation antigen CD27 in rheumatoid arthritis. Clin Immunol Immunopathol 1996;80:129-38.
48. dim, CD27-memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:844-54.
49. Cope AP, Londei M, Chu NR, Cohen SBA, Elliott MJ, Brennan FM, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/ CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
50. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, et al. Human memory T cells express increased levels of three adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL-1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988;140:1401-7.
51. Tedder TF, Clement LT, Cooper MD. Human lymphocyte differentiation antigens HB-10 and HB-11. II. Differential production of B-cell growth and differentiation factors by distinct helper T cell subpopulations. J Immunol 1985;134:2983-8.
52. Damle NK, Childs AL, Doyle LV. Immunoregulatory T lymphocytes in man. J Immunol 1987;139:1501-8.
53. Smith SH, Brown MH, Rowe D, Callard RE, Beverley PC. Functional subsets of human helper-inducer cells defined by a new monoclonal antibody. Immunology 1986;58:63-70.
54. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25:828-38.
55. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-9.
56. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 1996;173:269-72.